A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
Trial details
- Registry ID
- NCT06263231
- Drugs studied
- Eribulin, INT230-6, Pazopanib, Trabectedin
TrialRedline tracks 1 clinical trial sponsored by Intensity Therapeutics, Inc.: 1 Phase 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)NCT06263231 | Eribulin, INT230-6, Pazopanib, Trabectedin | Recruiting | 2027-12Estimated |
Names as written in the registry records.
NCT06263231 · Intensity Therapeutics, Inc.
Before: Active not recruiting. After: Recruiting.